N-(3-piperidylmethyl)methanesulfonamide | 886504-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(3-piperidylmethyl)methanesulfonamide
• 英文别名: N-(piperidin-3-ylmethyl)methanesulfonamide
• CAS: 886504-28-5
• 化学式: C₇H₁₆N₂O₂S
• 分子量: 192.282
• InChiKey: ITCJEUVIMIGZIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-piperidylmethyl)methanesulfonamide 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 19.0h， 生成 N-((1-(4-(6-(difluoromethyl)imidazo[1,2-b]pyridazin-3-yl)-6-morpholinopyridin-2-yl)piperidin-3-yl)methyl)methanesulfonamide
  参考文献：
  名称：

  [EN] GCN2 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用它们的方法。

  公开号：

  WO2019148132A1

文献信息

• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Chin Elbert

  公开号：US20100081658A1

  公开（公告）日：2010-04-01

  Compounds having the formula I wherein R 1 , R 2a , R 2b , R 2c , R 3 , Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下公式的化合物 I，其中 R1、R2a、R2b、R2c、R3、Y 和 p 的定义如本文所述，且 C2-C3 是单键或双键的化合物是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• One-Pot Parallel Synthesis of 5-(Dialkylamino)tetrazoles
  作者：Olena Savych、Yuliya O. Kuchkovska、Andrey V. Bogolyubsky、Anzhelika I. Konovets、Kateryna E. Gubina、Sergey E. Pipko、Anton V. Zhemera、Alexander V. Grishchenko、Dmytro N. Khomenko、Volodymyr S. Brovarets、Roman Doroschuk、Yurii S. Moroz、Oleksandr O. Grygorenko

  DOI：10.1021/acscombsci.9b00120

  日期：2019.9.9

  Two protocols for the combinatorial synthesis of 5-(dialkylamino)tetrazoles were developed. The best success rate (67%) was shown by the method that used primary and secondary amines, 2,2,2-trifluoroethylthiocarbamate, and sodium azide as the starting reagents. The key steps included the formation of unsymmetrical thiourea, subsequent alkylation with 1,3-propane sultone and cyclization with azide anion

  开发了5-（二烷基氨基）四唑的组合合成的两种方案。使用伯胺和仲胺，2,2,2-三氟乙基硫代氨基甲酸酯和叠氮化钠作为起始试剂的方法显示出最佳的成功率（67％）。关键步骤包括不对称硫脲的形成，随后与1,3-丙烷磺酸内酯的烷基化以及与叠氮化物阴离子的环化。通过这种方法合成了一个559个成员的氨基四唑文库。该方法覆盖的整个易于访问的（REAL）化学空间超过了700万种可行的化合物。
• NOVEL PHARMACEUTICAL
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1987827A1

  公开（公告）日：2008-11-05

  A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X1 represents an optionally substituted carbon atom, X2 represents an optionally substituted carbon atom, an oxygen atom and the like, W1 represents a nitrogen atom and the like, Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R3' represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R5' represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R1 represents an electron-withdrawing group, and the formula - - - represents a single bond or a double bond, or a salt thereof or a prodrug thereof.

  一种组合物，包含一种组分，该组分的结构式如下：其中，环A代表一个可选取代的5-至8环，环B代表一个可选进一步取代的4-至10环，环C代表一个可选进一步取代的苯环，X1代表一个可选取代的碳原子，X2代表一个可选取代的碳原子、氧原子等，W1代表一个氮原子等，Y11代表一个由式CR2R3'（其中，R2代表氢原子、氰基、硝基等，R3'分别代表键、氢原子、氰基、硝基等）表示的基团，Y21代表一个由式CR4R5'（其中，R4代表氢原子、氰基、硝基等，R5'分别代表键、氢原子、氰基、硝基等）表示的基团等，R1代表一个电子吸引基团，而式- - -表示单键或双键，或其盐或前药。
• Novel Pharmaceutical
  申请人：Yamaoka Masuo

  公开号：US20090042857A1

  公开（公告）日：2009-02-12

  A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X 1 represents an optionally substituted carbon atom, X 2 represents an optionally substituted carbon atom, an oxygen atom and the like, W 1 represents a nitrogen atom and the like, Y 11 represents a group represented by the formula CR 2 R 3′ (wherein R 2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R 3′ represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y 21 represents a group represented by the formula CR 4 R 5′ (wherein R 4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R 5′ represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R 1 represents an electron-withdrawing group, and the formula represents a single bond or a double bond, or a salt thereof or a prodrug thereof.

  一种组合物的组成式，该组合物是一种组织选择性的雄激素受体调节剂，其中环A代表可选取代的5-至8-环，环B代表可选取代的4-至10-环，环C代表可选取代的苯环，X1代表可选取代的碳原子，X2代表可选取代的碳原子、氧原子等，W1代表氮原子等，Y11代表由式CR2R3'（其中R2代表氢原子、氰基、硝基等，R3'代表键、氢原子、氰基、硝基等，分别）表示的基团，Y21代表由式CR4R5'（其中R4代表氢原子、氰基、硝基等，R5'代表键、氢原子、氰基、硝基等，分别）表示的基团等，R1代表电子吸引基团，式表示单键或双键，或其盐或前药。
• GCN2 inhibitors and uses thereof
  申请人：Merck Patent GmbH

  公开号：US10988477B2

  公开（公告）日：2021-04-27

  The present invention provides compounds inhibiting General amino acid Control Non-derepressible 2 kinase (“GCN2”), compositions thereof, and methods of using the same for treating various disorders, such as cancer.

  本发明提供了抑制通用氨基酸控制非去势 2 激酶（"GCN2"）的化合物、其组合物及其用于治疗各种疾病（如癌症）的方法。